The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS).

Cladribine is part of a wider trend in the NHS toward embracing time-saving innovations. Similar treatments, such as the ...

Broadening access to cladribine should help more patients avoid hospital and free up clinic time.

克拉屈滨，商品名Mavenclad，用于治疗患有高度活跃的复发缓解型多发性硬化症的成年人。 克拉屈滨 10 毫克；片剂。 克拉屈滨对多发性硬化症患者发挥治疗作用的机制尚未完全阐明，但被认为与通过损害 DNA 合成对 B 和 T 淋巴细胞产生细胞毒性作用有关，从而 ...

Cladribine is rapidly absorbed with maximum concentration reached 30–50 min after oral administration and 0–20% bound to plasma protein. The half-life varies from 5.6 to 7.6 h and 18.4 to 19.7 ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...

Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

“Broadening access to cladribine means thousands more patients will benefit from managing their treatment at home rather than regularly attending hospital appointments – as well giving women with MS ...